Ha habido 50 transacciones internas recientes registradas para Gossamer Bio, Inc. (GOSS), incluyendo 34 compras y 12 ventas. El total de compras internas fue valorado en $11.99M y el total de ventas internas en $3.09M.
Internos destacados con actividad reciente incluyen Hasnain Faheem, Christian Waage, Giraudo Bryan. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — GOSS
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2026-03-19 |
Hasnain Faheem |
President & CEO |
Devolución de Acciones |
47,000 |
$12.10 |
$568.7K |
- |
| 2026-03-19 |
Christian Waage |
EVP, Tech Ops and Admin |
Devolución de Acciones |
70,000 |
$1.36 |
$95.2K |
- |
| 2026-03-19 |
Giraudo Bryan |
COO/cfo |
Devolución de Acciones |
211,500 |
$2.16 |
$456.84K |
- |
| 2026-03-19 |
Peterson Caryn |
EVP, Regulatory Affairs |
Devolución de Acciones |
125,000 |
$0.84 |
$104.75K |
- |
| 2026-03-19 |
Aranda Richard |
Chief Medical Officer |
Devolución de Acciones |
157,500 |
$1.21 |
$190.58K |
- |
| 2026-03-19 |
Smith Robert Paul Jr |
Chief Commercial Officer |
Devolución de Acciones |
562,500 |
$2.88 |
$1.62M |
- |
| 2026-01-02 |
Hasnain Faheem |
President & CEO |
Concesión de RSU |
280,000 |
- |
- |
837,793 |
| 2026-01-02 |
Giraudo Bryan |
COO/cfo |
Concesión de RSU |
115,750 |
- |
- |
389,737 |
| 2026-01-02 |
Aranda Richard |
Chief Medical Officer |
Concesión de RSU |
93,750 |
- |
- |
463,106 |
| 2026-01-02 |
Smith Robert Paul Jr |
Chief Commercial Officer |
Concesión de RSU |
93,750 |
- |
- |
260,898 |
| 2025-06-25 |
Cox Russell J. |
Director |
Concesión de RSU |
115,000 |
$1.36 |
$156.4K |
115,000 |
| 2025-06-25 |
Daniel Thomas O |
Director |
Concesión de RSU |
115,000 |
$1.36 |
$156.4K |
115,000 |
| 2025-06-25 |
Quisel John D |
Director |
Concesión de RSU |
115,000 |
$1.36 |
$156.4K |
115,000 |
| 2025-06-25 |
Milligan Sandra |
Director |
Concesión de RSU |
115,000 |
$1.36 |
$156.4K |
115,000 |
| 2025-06-25 |
Drynan Skye |
Director |
Concesión de RSU |
115,000 |
$1.36 |
$156.4K |
115,000 |
| 2025-06-25 |
Nathan Steven D |
Director |
Concesión de RSU |
115,000 |
$1.36 |
$156.4K |
115,000 |
| 2025-03-04 |
Hasnain Faheem |
President & CEO |
Concesión de RSU |
1,540,000 |
$1.13 |
$1.74M |
1,540,000 |
| 2025-03-04 |
Christian Waage |
EVP, Tech Ops and Admin |
Concesión de RSU |
440,000 |
$1.13 |
$497.2K |
440,000 |
| 2025-03-04 |
Giraudo Bryan |
COO/cfo |
Concesión de RSU |
638,000 |
$1.13 |
$720.94K |
638,000 |
| 2025-03-04 |
Peterson Caryn |
EVP, Regulatory Affairs |
Concesión de RSU |
440,000 |
$1.13 |
$497.2K |
440,000 |
| 2025-03-04 |
Aranda Richard |
Chief Medical Officer |
Concesión de RSU |
572,000 |
$1.13 |
$646.36K |
572,000 |
| 2025-03-04 |
Smith Robert Paul Jr |
Chief Commercial Officer |
Concesión de RSU |
572,000 |
$1.13 |
$646.36K |
572,000 |
| 2024-06-24 |
Aranda Richard |
Chief Medical Officer |
Venta Informativa |
1,908 |
$0.66 |
$1.26K |
196,891 |
| 2024-06-21 |
Hasnain Faheem |
President & CEO |
Compra Informativa |
372,000 |
$0.67 |
$250.28K |
5,408,073 |
| 2024-06-18 |
Giraudo Bryan |
COO/cfo |
Compra Informativa |
100,000 |
$0.59 |
$59.11K |
480,010 |
| 2024-06-17 |
Smith Robert Paul Jr |
Chief Commercial Officer |
Compra Informativa |
25,000 |
$0.60 |
$15.05K |
25,000 |
| 2024-06-06 |
Cox Russell J. |
Director |
Concesión de RSU |
115,000 |
$0.60 |
$69K |
115,000 |
| 2024-06-06 |
Daniel Thomas O |
Director |
Concesión de RSU |
115,000 |
$0.60 |
$69K |
115,000 |
| 2024-06-06 |
Quisel John D |
Director |
Concesión de RSU |
115,000 |
$0.60 |
$69K |
115,000 |
| 2024-06-06 |
Milligan Sandra |
Director |
Concesión de RSU |
115,000 |
$0.60 |
$69K |
115,000 |
| 2024-03-27 |
Hasnain Faheem |
President & CEO |
Venta Informativa |
23,172 |
$1.16 |
$26.77K |
120,293 |
| 2024-03-27 |
Christian Waage |
EVP, Tech Ops and Admin |
Venta Informativa |
6,430 |
$1.16 |
$7.43K |
585,934 |
| 2024-03-27 |
Giraudo Bryan |
COO/cfo |
Venta Informativa |
6,430 |
$1.16 |
$7.43K |
92,737 |
| 2024-03-18 |
Peterson Caryn |
EVP, Regulatory Affairs |
Venta Informativa |
4,018 |
$1.33 |
$5.34K |
49,833 |
| 2024-03-18 |
Aranda Richard |
Chief Medical Officer |
Venta Informativa |
4,018 |
$1.33 |
$5.34K |
198,799 |
| 2024-03-11 |
Drynan Skye |
Director |
Desconocido |
- |
- |
- |
- |
| 2024-03-11 |
Drynan Skye |
Director |
Concesión de RSU |
230,000 |
$1.34 |
$308.2K |
230,000 |
| 2024-03-11 |
Nathan Steven D |
Director |
Desconocido |
- |
- |
- |
- |
| 2024-03-11 |
Nathan Steven D |
Director |
Concesión de RSU |
230,000 |
$1.34 |
$308.2K |
230,000 |
| 2024-01-02 |
Hasnain Faheem |
President & CEO |
Concesión de RSU |
1,312,500 |
$0.97 |
$1.27M |
1,312,500 |
| 2024-01-02 |
Christian Waage |
EVP, Tech Ops and Admin |
Concesión de RSU |
375,000 |
$0.97 |
$363.75K |
375,000 |
| 2024-01-02 |
Giraudo Bryan |
COO/cfo |
Concesión de RSU |
543,750 |
$0.97 |
$527.44K |
543,750 |
| 2024-01-02 |
Peterson Caryn |
EVP, Regulatory Affairs |
Concesión de RSU |
375,000 |
$0.97 |
$363.75K |
375,000 |
| 2024-01-02 |
Aranda Richard |
Chief Medical Officer |
Concesión de RSU |
487,500 |
$0.97 |
$472.88K |
487,500 |
| 2023-12-04 |
Smith Robert Paul Jr |
Officer |
Desconocido |
- |
- |
- |
- |
| 2023-12-04 |
Smith Robert Paul Jr |
Chief Commercial Officer |
Concesión de RSU |
1,500,000 |
$0.97 |
$1.45M |
1,500,000 |
| 2023-11-28 |
Quisel John D |
Director |
Desconocido |
- |
- |
- |
- |
| 2023-11-28 |
Quisel John D |
Director |
Concesión de RSU |
230,000 |
$0.69 |
$158.93K |
230,000 |
| 2023-11-20 |
Hasnain Faheem |
President & CEO |
Concesión de RSU |
437,500 |
$0.84 |
$366.63K |
437,500 |
| 2023-11-20 |
Christian Waage |
EVP, Tech Ops and Admin |
Concesión de RSU |
125,000 |
$0.84 |
$104.75K |
125,000 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
